Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Microb Cell Fact ; 18(1): 191, 2019 Nov 05.
Article in English | MEDLINE | ID: mdl-31690329

ABSTRACT

BACKGROUND: Aromatic amino acids and their derivatives are valuable chemicals and are precursors for different industrially compounds. p-Coumaric acid is the main building block for complex secondary metabolites in commercial demand, such as flavonoids and polyphenols. Industrial scale production of this compound from yeast however remains challenging. RESULTS: Using metabolic engineering and a systems biology approach, we developed a Saccharomyces cerevisiae platform strain able to produce 242 mg/L of p-coumaric acid from xylose. The same strain produced only 5.35 mg/L when cultivated with glucose as carbon source. To characterise this platform strain further, transcriptomic analysis was performed, comparing this strain's growth on xylose and glucose, revealing a strong up-regulation of the glyoxylate pathway alongside increased cell wall biosynthesis and unexpectedly a decrease in aromatic amino acid gene expression when xylose was used as carbon source. CONCLUSIONS: The resulting S. cerevisiae strain represents a promising platform host for future production of p-coumaric using xylose as a carbon source.


Subject(s)
Metabolic Engineering/methods , Propionates/metabolism , Saccharomyces cerevisiae/metabolism , Xylose/metabolism , Coumaric Acids , Gene Expression Profiling , Industrial Microbiology , Saccharomyces cerevisiae/genetics
2.
J Ind Microbiol Biotechnol ; 42(11): 1519-31, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26376869

ABSTRACT

Saccharomyces cerevisiae is one of the key cell factories for production of chemicals and active pharmaceuticals. For large-scale fermentations, particularly in biorefinery applications, it is desirable to use stress-tolerant industrial strains. However, such strains are less amenable for metabolic engineering than the standard laboratory strains. To enable easy delivery and overexpression of genes in a wide range of industrial S. cerevisiae strains, we constructed a set of integrative vectors with long homology arms and dominant selection markers. The vectors integrate into previously validated chromosomal locations via double cross-over and result in homogenous stable expression of the integrated genes, as shown for several unrelated industrial strains. Cre-mediated marker rescue is possible for removing markers positioned on different chromosomes. To demonstrate the applicability of the presented vector set for metabolic engineering of industrial yeast, we constructed xylose-utilizing strains overexpressing xylose isomerase, xylose transporter and five genes of the pentose phosphate pathway.


Subject(s)
Gene Expression Regulation, Fungal , Genetic Engineering/methods , Genetic Vectors/genetics , Saccharomyces cerevisiae/genetics , Aldose-Ketose Isomerases/genetics , Aldose-Ketose Isomerases/metabolism , Chromosomes, Fungal/genetics , Crossing Over, Genetic , Fermentation , Genetic Markers/genetics , Metabolic Engineering/methods , Pentose Phosphate Pathway/genetics , Saccharomyces cerevisiae/classification , Saccharomyces cerevisiae/metabolism , Xylose/metabolism
3.
Microb Cell Fact ; 11: 132, 2012 Sep 19.
Article in English | MEDLINE | ID: mdl-22992433

ABSTRACT

BACKGROUND: Plasmid DNA (pDNA) is a promising molecule for therapeutic applications. pDNA is produced by Escherichia coli in high cell-density cultivations (HCDC) using fed-batch mode. The typical limitations of such cultivations, including metabolic deviations like aerobic acetate production due to the existence of substrate gradients in large-scale bioreactors, remain as serious challenges for fast and effective pDNA production. We have previously demonstrated that the substitution of the phosphotransferase system by the over-expressed galactose permease for glucose uptake in E. coli (strain VH33) allows efficient growth, while strongly decreases acetate production. In the present work, additional genetic modifications were made to VH33 to further improve pDNA production. Several genes were deleted from strain VH33: the recA, deoR, nupG and endA genes were inactivated independently and in combination. The performance of the mutant strains was evaluated in shake flasks for the production of a 6.1 kb plasmid bearing an antigen gene against mumps. The best producer strain was cultivated in lab-scale bioreactors using 100 g/L of glucose to achieve HCDC in batch mode. For comparison, the widely used commercial strain DH5α, carrying the same plasmid, was also cultivated under the same conditions. RESULTS: The various mutations tested had different effects on the specific growth rate, glucose uptake rate, and pDNA yields (YP/X). The triple mutant VH33 Δ (recA deoR nupG) accumulated low amounts of acetate and resulted in the best YP/X (4.22 mg/g), whereas YP/X of strain VH33 only reached 1.16 mg/g. When cultivated at high glucose concentrations, the triple mutant strain produced 186 mg/L of pDNA, 40 g/L of biomass and only 2.2 g/L of acetate. In contrast, DH5α produced only 70 mg/L of pDNA and accumulated 9.5 g/L of acetate. Furthermore, the supercoiled fraction of the pDNA produced by the triple mutant was nearly constant throughout the cultivation. CONCLUSION: The pDNA concentration obtained with the engineered strain VH33 Δ (recA deoR nupG) is, to the best of our knowledge, the highest reported for a batch cultivation, and its supercoiled fraction remained close to 80%. Strain VH33 Δ (recA deoR nupG) and its cultivation using elevated glucose concentrations represent an attractive technology for fast and efficient pDNA production and a valuable alternative to fed-batch cultivations of commercial strains.


Subject(s)
Escherichia coli/metabolism , Plasmids/metabolism , Antigens/genetics , Antigens/metabolism , Biomass , Bioreactors/microbiology , Escherichia coli/growth & development , Escherichia coli Proteins/genetics , Gene Knockout Techniques , Genetic Engineering , Glucose/metabolism , Membrane Transport Proteins/genetics , Mumps virus/metabolism , Plasmids/genetics , Rec A Recombinases/genetics , Repressor Proteins/genetics , Vaccines, DNA/biosynthesis
SELECTION OF CITATIONS
SEARCH DETAIL
...